- Current report filing (8-K)
2009年11月18日 - 6:05AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
DC 20549
FORM
8-K
CURRENT
REPORT PURSUANT
TO
SECTION 13 OR 15(D) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date
of report (Date of earliest event reported): November 16, 2009
NOVADEL
PHARMA INC.
(Exact
Name of Registrant as Specified in Its Charter)
|
|
|
|
|
Delaware
|
|
001-32177
|
|
22-2407152
|
(State
or other jurisdiction
of
incorporation or organization)
|
|
(Commission
File No.)
|
|
(I.R.S.
Employer
Identification
No.)
|
25
Minneakoning Road
Flemington,
New Jersey 08822
(Address
of principal executive offices) (Zip Code)
(908)
782-3431
(Registrant’s
telephone number, including area code)
N/A
(Former
name or former address, if changed since last report)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (
see
General
Instruction A.2. below):
o
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
|
o
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
o
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
|
o
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
|
Item
2.02. Results
of Operations and Financial Condition.
On
November 16, 2009, NovaDel Pharma Inc. (“NovaDel”), a Delaware corporation,
issued a press release to report its financial results for the quarter ended
September 30, 2009. A copy of the press release is furnished pursuant to this
Item 2.02 as Exhibit 99.1 to this Current Report on Form 8-K.
This
Current Report on Form 8-K, as it relates to Item 2.02, is being furnished
pursuant to Item 2.02 and the press release is being furnished pursuant to Item
9.01 of this Current Report on Form 8-K, and shall not be deemed “filed” for
purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the
“Exchange Act”), or otherwise subject to the liabilities of that Section, nor
shall it be deemed incorporated by reference in any filing under the Securities
Act of 1933, as amended, or the Exchange Act.
Item
9.01. Financial
Statements and Exhibits
(d) Exhibits.
99.1 Press
release of NovaDel Pharma Inc. dated November 16, 2009, titled “NovaDel Reports
Financial Results for Third Quarter and Nine Months Ended September
30, 2009.”
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
NovaDel Pharma
Inc.
|
|
|
|
|
|
Date:
November 17, 2009
|
By:
|
/s/ STEVEN
B. RATOFF
|
|
|
|
Steven
B. Ratoff
|
|
|
|
Chairman,
Interim President and Chief Executive Officer and Interim Chief Financial
Officer
|
|
|
|
|
|
Novadel (AMEX:NVD)
過去 株価チャート
から 5 2024 まで 6 2024
Novadel (AMEX:NVD)
過去 株価チャート
から 6 2023 まで 6 2024